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Inflammation and Hyperreactivity in
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Zhilong Jiang 1,2,3* and Angela Haczku 1,2*
1Department of Internal Medicine, University of California, Davis, Davis, CA, United States, 2Department of Internal Medicine,
University of Pennsylvania, Philadelphia, PA, United States, 3Department of Pulmonary Medicine, Zhongshan Hospital,
Fudan University, Shanghai, China
Inhaled glucocorticoids form the mainstay of asthma treatment because of their
anti-inflammatory effects in the lung. Exposure to the air pollutant ozone (O3) exacerbates
chronic airways disease. We and others showed that presence of the epithelial-derived
surfactant protein-D (SP-D) is important in immunoprotection against inflammatory
changes including those induced by O3 inhalation in the airways. SP-D synthesis
requires glucocorticoids. We hypothesized here that O3 exposure impairs glucocorticoid
responsiveness (including SP-D production) in allergic airway inflammation. The effects
of O3 inhalation and glucocorticoid treatment were studied in a mouse model of allergic
asthma induced by sensitization and challenge with Aspergillus fumigatus (Af ) in vivo.
The role of O3 and glucocorticoids in regulation of SP-D expression was investigated
in A549 and primary human type II alveolar epithelial cells in vitro. Budesonide inhibited
airway hyperreactivity, eosinophil counts in the lung and bronchoalveolar lavage (BAL)
and CCL11, IL-13, and IL-23p19 release in the BAL of mice sensitized and challenged
with Af (p < 0.05). The inhibitory effects of budesonide were attenuated on inflammatory
changes and were completely abolished on airway hyperreactivity after O3 exposure
of mice sensitized and challenged with Af. O3 stimulated release of pro-neutrophilic
mediators including CCL20 and IL-6 into the airways and impaired the inhibitory effects of
budesonide on CCL11, IL-13 and IL-23. O3 also prevented budesonide-induced release
of the immunoprotective lung collectin SP-D into the airways of allergen-challenged
mice. O3 had a bi-phasic direct effect with early (<12 h) inhibition and late (>48 h)
activation of SP-D mRNA (sftpd) in vitro. Dexamethasone and budesonide induced sftpd
transcription and translation in human type II alveolar epithelial cells in a glucocorticoid
receptor and STAT3 (an IL-6 responsive transcription factor) dependent manner. Our
study indicates that O3 exposure counteracts the effects of budesonide on airway
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inflammation, airway hyperreactivity, and SP-D production. We speculate that impairment
of SP-D expression may contribute to the acute O3-induced airway inflammation.
Asthmatics exposed to high ambient O3 levels may become less responsive to
glucocorticoid treatment during acute exacerbations.
Keywords: asthma, allergy, ozone, budesonide, surfactant protein-D
INTRODUCTION
In the era of novel biologicals being introduced into the clinic,
glucocorticoids remain the main choice of asthma treatment
due to their significant anti-inflammatory, immunosuppressive,
and immunomodulatory effects (1, 2). A subset of patients
however is refractory to glucocorticoids (3–7), making their
asthma difficult to control (7). Glucocorticoid insensitivity can
be a primary genetic trait but more commonly it is acquired
during acute inflammatory exacerbations of airway disease (2, 4–
6, 8). Epidemiologic studies indicate a causal link between air
pollution and worldwide increases in asthma prevalence and
severity. Inhalation of O3, an ubiquitous, oxidizing, and toxic
air pollutant induces acute exacerbations with proinflammatory
mediator release, neutrophilic granulocyte influx and obstruction
of airways (9–15) and substantially worsens asthma morbidity
and mortality (16, 17). Data obtained from studies on mice (18),
dogs (19) rhesus macaques (20), healthy volunteers (21), and
asthma patients (22, 23) have been controversial on whether
glucocorticoids are effective to inhibit O3-induced exacerbation
of airway inflammation and airway hyperreactivity in asthma.
Further, the mechanisms of increased susceptibility of the
asthmatic airways to O3 and how glucocorticoid action is affected
by inhalation of this air pollutant remain unclear.
Individual susceptibility suggests that genetic predisposition
is involved in O3 responsiveness (24). This is corroborated by
strain dependence of the inflammatory response to O3 observed
in mice (14, 15, 25). In addition, increasing evidence supports
that a failure of protective immune mechanisms also likely plays
an important role in shaping the O3 effects in the lung. Surfactant
protein-D (SP-D), an epithelial cell product of the airways is
a critical factor in the maintenance of pulmonary immune
homeostasis.We have originally raised the importance of changes
in SP-D expression in resolving allergen and O3-induced airway
inflammation (26) by demonstrating that a differential ability
of Balb/c and C57BL/6 mice to respond to allergen (27) or O3
(28), was inversely associated with the amount of SP-D recovered
from the airways of these mouse strains (28, 29). Accordingly,
genetically low SP-D producer or SP-D deficient mice were
highly susceptible to and had a prolonged recovery period
from airway inflammation after allergen or O3 exposure (28,
Abbreviations: O3, Ozone; SP-D, Surfactant protein-D; sftpd, Surfactant protein-
D gene; Af, Aspergillus fumigatus; BAL, Bronchoalveolar lavage; AHR, Airway
hyperreactivity; Human primary type II airway epithelial (hAECII) cells; Cu
I, Curcurbitacin I; CCL-, C-C motif chemokine; IL-, Interleukin-; CXCL-,
Chemokine (CXC motif) ligand; STAT3, Signal transducer and activator of
transcription 3; qPCR, Quantitative, real-time polymerase chain reaction; ELISA,
Enzyme-linked Immunosorbent assay; DMSO, Dimethyl sulfoxide; R, Lung
Resistance; G, Tissue Damping; i. n., Intranasal; i.p., Intraperitoneal.
30, 31). O3-inhalation induced exacerbation of Th2-type airway
inflammation in allergen challenged mice was also associated
with the appearance of abnormal oligomeric molecular forms of
SP-D indicating that oxidative damage can cause conformational
change with a potential loss of its immunoprotective function
(32, 33).
While our lab and others showed that glucocorticoids are
necessary for expression of SP-D in epithelial cells (34–37),
we also demonstrated a feedback regulation between SP-D
and the Th2 cytokines IL-4/IL-13 (30) as well as IL-6 (28),
respectively. Interestingly, we found no glucocorticoid response
elements in the proximal promoter region of the SP-D gene
(sftpd) however, this region contains an evolutionarily conserved
STAT3/6 response element in a prominent proximal location.
Pertinent to this, IL-4/IL-13 (activators of STAT6) as well as IL-
6 (activator of STAT3) directly upregulated SP-D synthesis in
airway epithelial cells in vitro and in mice in vivo (28, 30). Lastly,
there are indications that STAT3 can be directly phosphorylated
by H2O2 (the molecular product of O3 when mixed in water)
treatment of airway epithelial cells in vitro (38).
We hypothesized that exposure to O3 interferes with the
effects of glucocorticoids on Af -induced airway inflammation
and hyperreactivity and, that O3 and glucocorticoid treatment
have antagonistic effects on SP-D expression and function in the
lung. To study these hypotheses we utilized our in vivo mouse
model of combined Af +O3 exposure and in vitro human airway
epithelial cell cultures.
MATERIALS AND METHODS
In vivo Studies
Balb/c mice were obtained from the Jackson laboratories (Bar
Harbor, ME) and bred in-house. All experiments were performed
on 8–10 weeks old mice. Experiments where mice were sensitized
and challenged with Af and exposed to air or O3 were carried out
as previously described (30, 39, 40). In brief, mice were sensitized
with 20 µg Af and alum by intraperitoneal injection (i.p.) on
days 0 and 7, then challenged with 25 µg Af by intranasal (i.n.)
instillation on day 13. In Figure 1, mice were treated with vehicle
(Dimethyl sulfoxide, DMSO) or budesonide (0.25 or 2.5 mg/kg)
i.n. at the time of Af challenge. 48 h post challenge, lung function
(enhanced pause, Penh) was measured using the Buxco R© system.
In Figures 2–5, mice followed the Af sensitization
and challenge protocol as described, however 84 h post
challenge/budesonide they were exposed to 3 ppm O3 or air
for 2 h. Animals were studied 96 h post Af challenge (12 h post
O3). These time points were selected to mimic O3-induced
exacerbation of allergic changes, because by 96 h post Af
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FIGURE 1 | Budesonide inhibited airway hyperreactivity induced by Af sensitization and challenge in Balb/c mice, in a dose-dependent manner. (A) Balb/c mice were
sensitized to 20 µg Aspergillus fumigatus (Af ), with alum (i.p.) on days 0 and 7. On day 13, mice were challenged with 25 µg Af (i.n.) and administered 0 (DMSO
vehicle only), 0.25 or 2.5 mg/kg budesonide. 48 h post-Af challenge mice were studied. (B) Lung function (enhanced pause, Penh) was measured by the Buxco®
system. Baseline measurements represent data collected over a 10min period (left panel). Methacholine dose response was established to increasing concentrations
of nebulized methacholine. Mean ± SEM of n = 4–18 (left panel: Dunett’s multiple comparison; right panel: Two-way ANOVA with Tukey’s multiple comparison).
challenge airway inflammation subsides while O3 exposure
induced inflammation peaks 12 h post exposure (Figures 2A,B)
(33, 40). That a 3 ppm inhaled dose in rodents results in O3
concentration in the lungs relevant to human exposure levels has
been experimentally validated by others, using oxygen-18-labeled
O3 (
18O3). Hatch et al. showed that exposure to
18O3 (0.4 ppm for
2 h) caused 4–5-fold higher 18O3 concentrations in humans than
in rats, in all of the BAL constituents measured (41). Rats exposed
to 2.0 ppm, had still less 18O3 in BAL than humans exposed to
0.4 ppm. The species discrepancies between the recoverable O3
levels in the lung are not entirely clear. It is thought however that
as rodents are obligate nose breathers (while humans breathe
through their nose and mouth), this reduces the delivered dose
of O3 to the lungs of rodents. Further, Slade et al. found that
after exposure to O3, mice react by a rapid decrease of core
temperature, a species and strain specific characteristics (42).
The recoverable 18O3 in the lung tissue was negatively associated
with the extent of hypothermia that significantly altered O2
consumption and pulmonary ventilation, explaining at least
partly, the interspecies differences seen in O3 susceptibility. In
addition, in pilot studies we also performed a careful assessment
of the biological effects on a range of 0.5–6.0 ppm O3 exposure.
Doses lower than 3 ppm did not elicit a significant inflammatory
response that would be commensurate with what is seen in
humans, in regards to BAL or peripheral blood neutrophilia,
upon O3 inhalation for 2 h. Higher than 3 ppm doses caused
observable respiratory distress especially in Balb/c mice. The O3
dose we used here therefore represents a level of exposure that is
well-tolerated by both Balb/c and C56BL/6 mice and that causes
a significant airway inflammatory response.
Lung function was measured using the Flexivent R©
system (Scireq, Montreal, Canada) in response to increasing
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FIGURE 2 | O3 induced airway inflammation and hyperreactivity and enhanced allergic airway changes in mice sensitized and challenged with Af. (A) Balb/c mice
were exposed to air or 3 ppm O3 for 2 h and studied at the indicated time points for airway inflammation. 12 h after O3 exposure, lung function to methacholine was
measured (Flexivent®) prior to BAL. (B) BAL neutrophils and eosinophils were quantified by differential cell counts on cytospin preparations multiplied by the total cell
counts recovered from the BAL (Countess®). (C) O3 exposed mice and air exposed controls were studied for methacholine responsiveness 12 h later. Mean ± SEM
of n = 6 **p < 0.01 Two-way ANOVA with Tukey’s multiple comparison’s test (air vs. O3 exposure). (D) Balb/c mice were sensitized to 20 µg Aspergillus fumigatus
(Af ), with alum (i.p.) on days 0 and 7. On day 13, mice were challenged with 25 µg Af (i.n.). 82 h post-Af challenge, mice were exposed to air or 3 ppm O3 for 2 h,
then 12 h later (96 h post-Af challenge), lung function was measured (Flexivent® ) and BAL was harvested. (E) BAL neutrophils (live Ly6G+CD11b+ cells) and
eosinophils (live CD11c−Siglec-F+ cells) were quantitated by FACS analysis. The absolute numbers of eosinophils and neutrophils were calculated by multiplying the
percentage of cells determined by flow cytometric gating with the total numbers of cells/lung (Countess®). Mean ± SEM of n = 6; **p < 0.01 Student’s t-test (air vs.
O3). (F) Lung function (airway resistance, Raw) was measured as indicated. Mean ± SEM of n = 6; ***p < 0.001 Two-way ANOVA with Tukey’s multiple comparison’s
test (air vs. O3 exposure).
concentrations of inhaled methacholine. BAL and lung cells
were harvested to study inflammatory cells by flow cytometry.
Following collection of BAL, 10mL ice-cold PBS was injected
into the right ventricle to perfuse the lung. The lung lobes
were then carefully removed and snipped into small pieces
before undergoing digestion with Liberase TL (Millipore Sigma,
Burlington, MA) for 40min at 37◦C on a shaker. Digested whole
lung homogenate was filtered through a 70µm cell strainer to
create a single cell suspension for flow cytometric analysis. In
cell-free BAL supernatant, a custom mouse magnetic Luminex
assay was utilized to study cytokines and chemokines while
SP-D was measured by western blot, native gel electrophoresis
(structure) or sandwich ELISA (quantity). All mouse procedures
were reviewed and approved by the University of California,
Davis, and University of Pennsylvania Institutional Animal Care
and Use Committees.
Flow Cytometry
BAL and lung cells were harvested and single cell suspensions
were prepared as previously described for analysis by flow
cytometry (40). Fluorescently-conjugated monoclonal antibodies
were purchased from Biolegend (San Diego, CA), BD Biosciences
(San Jose, CA), or eBioscience (San Diego, CA). Single cell
suspensions were incubated with antibodies targeting surface
markers for 20min at 4 degrees C in the dark. In the BAL
samples, the following antibodies were used: APC-Cy7-CD11c,
PE-Siglec F, PE-Cy7-CD11b, PerCP-Cy5.5-Ly6G. In the lung
digest suspensions, neutrophils, and eosinophils were identified
using APC-Cy7-CD11c, PE-Siglec F, and PerCP-Cy5.5-Ly6G.
Live/dead Aqua was used in the panels throughout the study to
exclude dead cells. Flow cytometry was performed on a Fortessa
(BD Biosciences, San Jose, CA) and data was analyzed using
FlowJo software (Ashland, OR).
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FIGURE 3 | The inhibitory effects of budesonide on Af-induced airway inflammation were attenuated and on airway hyperreactivity were completely abolished by O3
exposure in sensitized and challenged mice. (A) Balb/c mice were sensitized to 20 µg Aspergillus fumigatus (Af ), with alum (i.p.) on days 0 and 7. On day 13, mice
were challenged with 25 µg Af (i.n.) and administered 2.5 mg/kg budesonide or vehicle (DMSO). 82 h post-Af challenge, mice were exposed to air or 3 ppm O3 for
2 h, then 12 h later (96 h post-Af challenge), lung function was measured (Flexivent® ), and BAL and lungs were harvested. (B) Representative gating of BAL and lung
neutrophils (live Ly6G+CD11b+ cells) and eosinophils (live CD11c−Siglec-F+ cells). (C) The absolute numbers of eosinophils and neutrophils were calculated by
multiplying the percentage of cells determined by flow cytometric gating with the total numbers of cells/lung or BAL (Countess®). Mean ± SEM of n = 6; #p < 0.05
Student’s t-test (vehicle vs. budesonide). (D) Lung resistance and tissue damping results were calculated as % change from baseline. The difference between the
vehicle and budesonide treatment is depicted (by subtracting the individual % change from baseline values from the vehicle treatment average at each methacholine
concentration). Mean ± SEM of n = 6–14; ***p < 0.001 (Af+Air+Bud vs. Af+O3+Bud) Two-way ANOVA with Tukey’s multiple comparison’s test.
FIGURE 4 | O3 upregulated BAL IL-6, CXCL2, and CCL20 in a budesonide-resistant manner and reversed the inhibitory effects of budesonide on CCL11, IL-13, and
IL-23 expression in mice sensitized and challenged with Af. Cell-free BAL supernatant was assessed for the indicated cytokines and chemokines by a R&D mouse
magnetic Luminex Assay (pg cytokine/µg BAL protein). Mean ± SEM of n = 3; *p < 0.05, #p < 0.05 Student’s t-test [vehicle vs. budesonide (#) or air vs. O3 (*)].
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FIGURE 5 | O3 inhibited budesonide-induced SP-D expression in Af-challenged mice and caused SP-D de-oligomerization in the BAL. (A) Cell-free BAL supernatant
was assessed for total protein by BCA assay. (B) BAL SP-D was measured by ELISA. (C) Native-PAGE western blot was used to study SP-D structure. Native (intact)
SP-D is the band that due to its molecular size remain on the top of the gel. Due to the variability of migratory capabilities of the de-oligomerized SP-D components,
these appear as a “smear” throughout the gel. (D) SP-D optical density by Image J analysis; ratio over the mean value of “air+vehicle” control group data. Mean ±
SEM or n = 5–6; *p < 0.05 air vs. O3, #p < 0.05 vehicle vs. budesonide, Two-way ANOVA with Tukey’s multiple comparison’s test.
FIGURE 6 | Time dependent effects of O3 on budesonide-induced sftpd mRNA in A549 cells in vitro. (A) A549 cells were incubated for 2 h with budesonide or vehicle
(DMSO) and exposed to air or 300 ppb O3. 1.5 or 48 h after exposure/treatment ended, cells were harvested and processed for RNA extraction. (B,C) sftpd mRNA
was measured by qPCR. Fold over air+vehicle values are shown. Representative of three independent experiments.
Luminex Assay
Cytokines and chemokines were assayed in the BAL via a custom
Magnetic Mouse Luminex Assay (R&D System, Minneapolis,
MN). C-C motif chemokine 11 (CCL11), Interleukin-23p19 (IL-
23p19), IL-13, IL-6, Chemokine (CXC motif) ligand 2 (CXCL2),
and CCL20 were measured in the premixed kit. BAL fluid was
first concentrated using a 2mL, 3 k Amicon Ultra Centrifugal
Filter (Millipore Sigma, Burlington, MA) spun at 3,000 g for
30min. The kit was performed following the instructions from
the manufacturer.
BAL SP-D Analysis
Total protein concentration was measured by the BCA Assay
(Thermo Fisher Scientific, Waltham, MA). BAL SP-D was
assayed by sandwich ELISA using our in-house generated
monoclonal and polyclonal antibodies as previously described
(33). BAL SP-D was also measured by native gel electrophoresis
(33) to assess the tertiary structure of SP-D, which is critical
to maintain its anti-inflammatory functions (43, 44). Proteins
were transferred to a nitrocellulose membrane (Thermo Fisher
Scientific, Waltham, MA). Goat anti-mouse SP-D (1:2,000, R&D
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FIGURE 7 | Glucocorticoid receptor-induced sftpd mRNA and protein expression is facilitated by STAT3/6 binding. (A) Schematic of the proximal promoter region of
the human SP-D gene (sftpd) lacking glucocorticoid response elements. The approximate positions of C/EBP (orange ovals) and STAT3/6 (green rectangle) binding
are depicted. Negative values indicate the number of base pairs relative to the start of transcription. (B) Human Primary Type II alveolar epithelial (hAECII) cells were
incubated for 2 h with dexamethasone (Dex), curcurbitacin I (Cu I), and RU486 as indicated. 48 h later, cells were harvested and SP-D was studied by western blot
(protein, relative expression to GAPDH) and qPCR (sfptd mRNA). (C) qPCR of sftpd (fold over no dexamethasone). (D–F) SP-D protein was studied by western blot,
compared to control GAPDH. Optical density of SP-D and GAPDH by Image J analysis; GAPDH was subtracted from SP-D density then the ratio over the mean value
of “no treatment” group was calculated. Mean ± SEM of n = 6 (C) or n = 3 (D–F). *p < 0.05, **p < 0.01 vs. “no treatment”; #p < 0.05, ##p < 0.01 vs. the same
concentration of Dex or Bud alone; One-way ANOVA with Bonferroni’s multiple comparison’s test (D–F). Western blots are representative of three independent
experiments.
Systems, Minneapolis, MN) was the primary antibody while
donkey anti-goat antibody coupled to horseradish peroxidase
(1:10,000 GE Healthcare Life Sciences, Marlborough, MA) was
the secondary antibody. SP-D signal was detected using the ECL
Western Blotting Substrate (Thermo Fisher Scientific, Waltham,
MA) on film (ECL Hyperfilm, GE Healthcare Life Sciences,
Marlborough, MA). Image J (National Institutes of Health,
Rockville, MD) analysis was used to determine the optical density
of SP-D bands.
In vitro Studies
Human primary type II airway epithelial (hAECII) cells were
acquired from normal human lung tissues from NDRI (National
Disease Research Interchange). A549 cells were purchased
from ATCC (Manassas, Virginia). Dexamethasone, budesonide,
curcurbitacin I (Cu I), and RU486 was purchased from Millipore
Sigma (Burlington, MA). A549 cells are a human type II alveolar
epithelial cell line used by our laboratory and others (45–47) to
model functions including expression of mRNA for SP-D. We
used these readily available cells to establish conditions of SP-D
mRNA expression upon treatment with ozone and budesonide
(Figure 6). The budesonide effects were then recapitulated in
primary hAECII cells (Figure 7). A549 cells were cultured in
DMEM supplemented with 10% fetal bovine serum and 1%
penicillin/streptomycin (Thermo Fisher Scientific, Waltham,
MA). Primary hAECII cells were cultured in DMEM-H21 plus
F-12 Ham’s (1:1) supplied with 5% fetal bovine serum, 100 U/ml
penicillin, 0.1 mg/ml streptomycin, 2mM L-glutamine. D-valine
(Invitrogen) prevented growth of fibroblasts. hAECII cells were
treated with budesonide/dexamethasone for 2 h, with or without
RU486 and Cu I added to the culture. A549 cells were treated
with budesonide and exposed to air or O3 (300 ppb) for 2 h,
which was generated as previously described (31). DMSO was
used as the vehicle control in the in vitro studies. At the time
points indicated in the figure, cells were harvested for analysis of
sftpd mRNA (qPCR) or SP-D protein (western blot). Cells were
harvested in TRIzol reagent (Thermo Fisher Scientific, Waltham,
MA) for mRNA analysis by qPCR or RIPA buffer (Thermo Fisher
Scientific, Waltham, MA) for protein analysis by western blot.
For the western blots, total intracellular protein was measured
by the BCA assay, then 20 µg protein was loaded for each
lane. The primary antibody was goat anti-SP-D (1:500). The
secondary antibody was HRP anti-goat IgG (1:1,000). For control
antibodies, the primary was rabbit anti-GAPDH (1:1,000) and
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the secondary was HRP anti-rabbit (1:5,000). All antibodies were
purchased from Santa Cruz Biotechnology (Dallas, TX). Image J
(National Institutes of Health, Rockville, MD) analysis was used
to determine the optical density of SP-D bands. For the qPCR,
RNA was extracted from the TRIzol by chloroform layering
and isopropanol precipitation, then reverse transcribed into
cDNA via the QuantiTect Reverse Transcription Kit (Qiagen,
Hilden, Germany). qPCR was performed on the recovered
cDNA using SYBR green reagents (Applied Biosystems, Foster
City, CA) on a ViiA 7 Real-Time PCR system (Thermo Fisher
Scientific, Waltham, MA). Fold change was calculated using the
11Ct method, first normalizing values to GAPDH. Human SP-
D primer with sequence of 5′-ACACAGGCTGGTGGACAG-3′
(sense); 5′-TGTTGCAAGGCGGCATT-3′ (anti-sense) were used
to produce 61 bp products.
Statistical Analysis
All statistics were performed using Prism v7 software (GraphPad
Inc., La Jolla, CA). Data are expressed as mean ± SEM and are
representative of at least 2 independent experiments. A Student’s
t-test was used to compare vehicle vs. budesonide or air vs. O3.
A One-way ANOVA with Tukey’s multiple comparison’s test was
used in the budesonide dose response experiment (Figure 1). A
Two-way ANOVA with Tukey’s multiple comparison’s test was
used when comparing all experimental groups. A p < 0.05 was
considered statistically significant.
RESULTS
Budesonide Inhibited Airway
Hyperreactivity Induced by Af Sensitization
and Challenge in Balb/c Mice in a
Dose-Dependent Manner
Inhaled glucocorticoids improve lung function and airway
inflammation in allergic asthma (1, 48, 49) but their effectiveness
in acute asthma exacerbations are subject of on-going
investigations (49–51). We developed a model in which
mice were sensitized (i.p.) and challenged with Af at the time
of budesonide administration (i.n.) (Figure 1A). To establish
the dose-dependent effects of budesonide on methacholine
responsiveness we used Penh (enhanced pause), a non-invasive
measure of airway obstruction, because it enabled us to obtain
data from multiple individual animals simultaneously and
complete a study using a large number of mice. These results
showed that sensitization and challenge to Af significantly
increased baseline Penh and methacholine responsiveness and
that budesonide significantly inhibited airway hyperreactivity
to methacholine at 2.5 mg/kg dose (Figure 1B). For the
subsequent experiments presented in this paper we used this
budesonide dose and confirmed its inhibitory effects on allergic
airway hyperreactivity by the invasive FlexiVent R© system
(Figures 2C,F, 3D). These data also provided the basis for
the subsequent studies on the effects of O3 on allergic airway
inflammation and glucocorticoid responsiveness.
O3 Induced Airway Inflammation and
Hyperreactivity and Enhanced Allergic
Airway Changes in Mice Sensitized and
Challenged With Af
To establish the time course of O3 induced airway inflammation,
Balb/c mice were exposed to air or 3 ppm O3 for 2 h and studied
at several time points afterwards (Figure 2A). Neutrophil influx
into the airways peaked 12 h after O3 exposure (Figure 2B).
O3 exposed mice and air exposed controls were studied for
methacholine responsiveness at the 12 h time point. O3 induced
a significant increase in methacholine responsiveness compared
with air exposed controls (p < 0.01) (Figure 2C). To investigate
the effects of O3 on allergic airway inflammation Balb/c mice
were sensitized and challenged with Af. In this model the acute
inflammatory changes resolve by 96 h after allergen challenge.
We therefore studied the mice at this time point, but we also
exposed them to either air or O3 12 h before (Figure 2D). BAL
neutrophils and eosinophils were quantitated by FACS analysis
(the gating strategy is shown in Figure 3B). O3 exposure clearly
enhanced numbers of eosinophils and neutrophils in the airways
of Af sensitized and challenged mice in comparison with air
exposure (p < 0.01; Figure 2E). In addition, lung resistance to
methacholine challenge was also significantly amplified in the O3
exposed animals (p < 0.001; Figure 2F). These results confirm
our previous findings (39) and strongly indicate that O3 induces
airway hyperreactivity on its own and that it enhances airway
changes in allergen sensitized and challenged animals.
The Inhibitory Effects of Budesonide on
Af-Induced Airway Inflammation Were
Attenuated, and on Airway Hyperreactivity
Were Completely Abolished by O3
Exposure in Sensitized and Challenged
Mice
Experiments in dogs (19) our previous studies in healthy
volunteers (52) and investigations in mild asthmatics (53)
showed that glucocorticoid treatment inhibited O3-induced
inflammation in the airways. However, how would O3 alter the
inhibitory effects of budesonide on allergic airway inflammation
and hyperreactivity has not been documented.
To study the hypothesis that O3 impairs the anti-
inflammatory effects of budesonide, Balb/c mice were
sensitized and challenged with Af as described, and were
intranasally treated with 2.5 mg/kg budesonide or vehicle.
82 h post-Af challenge mice were exposed to air or 3 ppm
O3 for 2 h, then 12 h later (96 h post-Af challenge), lung
function was measured (Flexivent R©), and BAL and lungs were
harvested (Figure 3A). BAL eosinophils (live Siglec-F+CD11c−
cells) and neutrophils (live Ly6G+CD11b+ cells) and lung
eosinophils (live CD45+CD11c−Siglec-F+) and neutrophils (live
CD45+CD11c−Ly6G+) were analyzed by FACS from single cell
suspensions as shown in Figure 3B. Budesonide significantly
suppressed eosinophil (not neutrophil) numbers both in the
BAL and the lung in air exposed but not in O3 exposed mice
(Figure 3C). Strikingly, inhibition of lung resistance (upper
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panel) and tissue damping (lower panel) by budesonide seen in
air exposedmice (gray plain squares) was completely abolished in
O3-exposed mice (gray hatched squares, p < 0.001, Figure 3D).
These data indicated that the inhibitory effects of budesonide on
Af -induced airway inflammation were attenuated and on airway
hyperreactivity were completely abolished by O3 exposure in
sensitized and challenged mice.
O3 Upregulated BAL IL-6, CXCL2 and
CCL20 in a Budesonide-Resistant Manner
and Reversed the Inhibitory Effects of
Budesonide on CCL11, IL-13, and IL-23
Expression in Mice Sensitized and
Challenged With Af
Since O3 mitigated the inhibitory effect of budesonide on
airway eosinophilia and airway hyperreactivity, we wanted to
investigate the underlying mediator profile. We measured BAL
CCL11 (eotaxin, an eosinophil chemoattractant), IL-23p19, IL-
6, CXCL2 (pro-neutrophilic mediators), CCL20 (a lymphocyte
chemoattractant), and IL-13 (known to prime smooth muscle
cells for airway hyperreactivity). O3 strongly induced BAL IL-
6, CXCL2, and CCL20 in a budesonide-independent manner
(Figure 4). Meanwhile, budesonide significantly reduced BAL
CCL11 showed a trend for reduction of IL-13 (p = 0.07) and
IL-23p19 (p = 0.05) in the BAL of air exposed, but not O3
exposed mice (Figure 4, lower panels). These data suggested that
O3 induced pro-neutrophilic factors regardless of budesonide
treatment, and that the suppressive effects of budesonide on
eosinophilia and airway hyperreactivity-inducing factors was
attenuated by O3.
O3 Caused SP-D De-oligomerization and
Inhibited Budesonide-Induced SP-D
Expression in the BAL
We and others previously showed that SP-D plays an important
role in suppressing proinflammatory mediator release in allergen
or O3-induced airway inflammation (28–30, 54) and that
production of SP-D required the presence of glucocorticoids in
airway epithelium (34–37). Further, we found that O3-induced
airway inflammation in allergen challenged mice resulted in
abnormal oligomeric molecular forms of SP-D indicating that
oxidative damage can cause conformational changes with a
potential inactivation of SP-D’s immunoprotective function (28,
32, 33). Here we wanted to investigate how the combination of
allergen with O3 exposure would alter the glucocorticoid effects
on SP-D expression.
Assessment of total BAL protein levels showed that those
were returned to normal 96 h after Af challenge, indicating
inflammatory resolution in air exposed mice. In O3 exposed mice
however, BAL protein levels were significantly elevated indicating
acute inflammation that was not prevented by budesonide
treatment (Figure 5A). As expected on the basis of previous
investigations (34–37) budesonide significantly increased BAL
SP-D in air exposed mice. Importantly, this budesonide effect
on SP-D expression was lost in O3 exposed mice (Figure 5B).
By native gel electrophoresis, structurally intact SP-D was found
at the top of the gel and did not separate from the well, while
de-oligomerized SP-D was resolved as a smear (Figure 5C).
Native SP-D density was not statistically different between the
groups studied (Figure 5C). O3 caused de-oligomerization of SP-
D in the BAL of mice sensitized and challenged with Af. This
change was prevented by budesonide treatment (gray hatched
bar, Figure 5D). Our data suggested that budesonide induction of
SP-D is inhibited by O3. We speculate that in budesonide treated
mice SP-D was indirectly protected from de-oligomerization
possibly as a result of inhibition of eosinophils (the main source
of iNOS and nitric oxide) in the lungs of mice (Figure 3C).
Time Dependent Effects of O3 on
Budesonide-Induced sftpd mRNA in A549
Cells in vitro
We previously showed that IL-6 directly induced SP-D in type
II alveolar epithelial cell cultures (28). This is interesting in light
of O3 while strongly inducing IL-6 (Figure 4), did not increase
SP-D 12 h after exposure, but in fact it prevented the stimulatory
effects of budesonide on SP-D release in the airways of mice
(Figures 5A,B). To better understand the mechanisms of how
budesonide and O3 regulate SP-D expression we used A549 cells,
a readily available human type II alveolar epithelial cell line that
models functions such as expression of the SP-D gene (sftpd,
Figure 6A). To confirm our findings, the budesonide effects were
then recapitulated in primary human type II alveolar epithelial
cells (hAECII, Figure 7). O3 exposure of A549 cells inhibited
sftpd expression 1.5 h later, but by 48 h post exposure this effect
was reversed into an induction of the sftpd gene (Figure 6B).
Budesonide induced sftpdmRNA in A549 cells exposed to air. O3
completely prevented the budesonide induction of the sftpd gene
1.5 h later. However, by 48 h O3 and budesonide synergistically
increased sftpdmRNA (Figure 6C). These results are in line with
our previous in vivo study on Balb/c mice (28) and suggest that
O3 acts on sftpd transcription in a bi-phasic manner with an early
phase inhibition (<12 h) and a late phase activation>48 h. Based
on these and our previous findings on IL-6 we speculated that
budesonide andO3 may interact on a common signaling pathway
involved in SP-D transcription in airway epithelial cells.
Glucocorticoid Receptor-Induced sftpd
mRNA Transcription Is Facilitated by
STAT3/6 Binding
The proximal promoter region of the human SP-D gene (sftpd)
has binding elements for C/EBP, NFAT, AP1, HNF-3, and
STAT3/6 that all contribute to transcription of SP-D (Figure 7A)
(55). Dexamethasone induced lung SP-D in mice at the level
of transcription in the absence of a full glucocorticoid response
element in the proximal promoter region of sftpd. Zhang and
colleagues previously reported that STAT3 can act as a co-
activator in glucocorticoid receptor signaling (56). To test if
the glucocorticoid receptor works in concert with the STAT3/6
binding element to induce SP-D we studied primary hAECII
cells using a specific inhibitor of STAT3 (cucurbitacin Cu
I) (57) and the glucocorticoid receptor (RU486). We treated
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human primary type II alveolar epithelial (hAECII) cells with
budesonide and dexamethasone in vitro and studied SP-D
mRNA (qPCR for sftpd) and protein (western blot for SP-
D) expression (Figure 7B). We used dexamethasone in the in
vitro experiments as a positive control because it is a well-
characterized glucocorticoid that induces SP-D (35). Indeed,
dexamethasone induced sftpd expression in human primary
type II aleveolar epithelial cells that was abolished in the
presence of Cu I or RU486 (Figure 7C). Similarly, Cu I and
RU486 inhibited dexamethasone and budesonide-induced SP-
D protein in hAECII cells (Figures 7D–F). Optical density
analysis by Image J analysis confirmed that antagonism of
the glucocorticoid receptor or STAT3 impaired dexamethasone-
induced SP-D (Figures 7D,E) and that budesonide induced SP-
D in a glucocorticoid receptor dependent manner (Figure 7F).
These data suggested that glucocorticoid-induced SP-D synthesis
was dependent on glucocorticoid receptor and STAT3 activation.
DISCUSSION
We report here the effects of O3 on intranasal budesonide
treatment in allergic airway inflammation and hyperreactivity,
implicate the alterations in SP-D expression in the O3-induced
airway changes and propose the involvement of STAT3 in
glucocorticoid signaling during sftpd transcription. Our study
raises the significance of air pollution in the regulation of
respiratory immunity and treatment responsiveness in asthma.
Inhaled glucocorticoids are currently the main choice
for asthma treatment because they can profoundly improve
lung function, alleviate airway inflammation and airway
hyperreactivity (1, 48, 49) but their effectiveness in acute asthma
exacerbations is subject of on-going debate (49–51, 58–60).
Studies on asthma exacerbations caused by exposure to air
pollutants are limited (61, 62) and the available experimental
data on animals (18–20) and humans (21–23) are unclear
on whether inhaled corticosteroids are effective to treat O3-
induced airway inflammation and/or airway hyperreactivity in
asthma. We wanted therefore to further investigate the effects
of budesonide on O3-induced exacerbation of allergic airway
changes. We found that in the Af sensitization and challenge
model airway hyperreactivity to methacholine was inhibited by
budesonide at 2.5 mg/kg dose. To mimic asthma exacerbation,
we sensitized and challenged Balb/c mice with Af, waited for 4
days for the acute inflammation to subside and then exposed
the mice to O3. Our results show that O3 exposure induced
airway hyperreactivity on its own and significantly enhanced lung
resistance to methacholine and the numbers of eosinophils and
neutrophils in the airways of Af sensitized and challenged mice
confirming previous findings (39). To study the hypothesis that
O3 impairs the anti-inflammatory effects of budesonide, mice
were intranasally treated with 2.5 mg/kg budesonide or vehicle.
Budesonide significantly suppressed eosinophil (not neutrophil)
numbers both in the BAL and the lung in air exposed but not
in O3 exposed mice. Strikingly, inhibition of lung resistance by
budesonide (seen in air exposed mice) was completely abolished
by O3 exposure.
In various experimental conditions budesonide was
previously shown to inhibit mediators relevant to O3-induced
airway changes such as IL-6 (63), CCL11 (64), CXCL2 mRNA in
the lung (65) and IL-13-induced ex vivo airway hyperreactivity
(66), while CCL20 was actually stimulated by budesonide
in asthmatic airway epithelial cells (67) and there is no
data in the literature on the effects of budesonide on IL-
23p19. O3 upregulated BAL IL-6, CXCL2, and CCL20 in a
budesonide-resistant manner and reversed the inhibitory effects
of budesonide on CCL11, IL-13, and IL-23p19 expression
in mice sensitized and challenged with Af. Induction of
CCL20 by O3 is interesting because CCL20 was thought to
be responsible for recruitment of neutrophils into the airways
conveying budesonide resistance (67). The role of CCL20
in O3-induced resistance to the budesonide effects however
would need further confirmation. The reduction seen in BAL
CCL11 and IL-23p19 of the budesonide treated air exposed
animals corresponded with decreased BAL eosinophil and
neutrophil counts, while reduced IL-13 matched the observed
inhibition of airway hyperreactivity in the same animals. Since
O3 exposure prevented these budesonide effects, it is possible
that these mediators are directly involved in the immunologic
and physiologic response to combined Af and O3 exposure. On
the other hand, O3 induced IL-6, CXCL2, and CCL20 was not
altered by budesonide treatment and thus may be implicated
in the observed neutrophilic inflammation caused by O3 under
allergic conditions. Our results are significant because they
reproduce a glucocorticoid resistant airway inflammation and
the hallmark characteristics of severe neutrophilic asthma
exacerbation (68, 69).
SP-D plays an important role in suppressing proinflammatory
mediator release in allergen or O3-induced airway inflammation
(29, 30, 54). Levels of SP-D expression in the lung are correlated
to disease severity in asthma (70, 71). Therapeutics that boost
SP-D expression are thought to improve asthma symptoms
(70–72). Indeed production of SP-D requires the presence of
glucocorticoids in airway epithelium (34–37). Our previous work
showed that O3 exposure induced the expression of SP-D in the
BAL >48 h later, as a protective mechanism (28, 33, 39) but O3-
induced airway inflammation in allergen challenged mice also
led to appearance of abnormal oligomeric molecular forms of
SP-D indicating that oxidative stress can cause conformational
changes that can inactivate SP-D’s immunoprotective function
(28, 32, 33). Such de-oligomerization was due to S-nitrosylation
of SH bonds responsible for holding the dodecameric SP-D
together (43, 44, 73). S-nitrosylation of SP-D requires NO,
resulted from increased iNOS activity produced by the large
numbers of activated inflammatory cells, particularly eosinophils
in the allergen and O3-exposed lung (33, 43, 44, 73). Here we
wanted to know if the combination of allergen with O3 exposure
would alter the glucocorticoid effects on SP-D expression and
whether budesonide treatment would affect O3-induced SP-
D de-oligomerization. As expected on the basis of previous
investigations (34–37, 72) budesonide significantly increased
BAL SP-D in air exposed mice. Importantly, this budesonide
effect on SP-D expression was lost in O3 exposed mice. O3 in
addition caused de-oligomerization of SP-D in the BAL of mice
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sensitized and challenged with Af. This change was prevented by
budesonide treatment. We speculate that in budesonide treated
mice SP-D was indirectly protected from de-oligomerization
possibly as a result of inhibition of eosinophils (the main source
of iNOS and nitric oxide) in the lungs of mice. Taken together,
our data suggested that budesonide induction of SP-D is inhibited
by O3 revealing a novel mechanism by which O3 antagonizes the
therapeutic benefits of this inhaled glucocorticoid. We propose
that budesonide enhances SP-D expression thereby amplifying its
local therapeutic effects in asthma.
We previously showed that IL-6 directly induced SP-D in type
II alveolar epithelial cell cultures (28). This is interesting in the
light that O3 while strongly inducing IL-6, did not increase SP-
D 12 h after exposure, but in fact it prevented the stimulatory
effects of budesonide on SP-D release in the airways of mice.
To better understand the mechanisms of how budesonide and
O3 regulate SP-D expression we used A549 cells, a readily
available human type II alveolar epithelial cell line that models
functions such as expression of the SP-D gene (sftpd). To confirm
our findings, the budesonide effects were then recapitulated in
primary human type II alveolar epithelial cells. O3 exposure of
A549 cells inhibited sftpd expression 1.5 h later, but by 48 h post
exposure this effect was reversed into an induction of the sftpd
gene. Budesonide induced sftpd mRNA in A549 cells exposed
to air. O3 completely prevented the budesonide induction of
the sftpd gene 1.5 h later. However, by 48 h O3 and budesonide
synergistically increased sftpd mRNA. These results are in line
with our previous in vivo study on Balb/c mice (28) and suggest
that O3 acts on sftpd transcription in a bi-phasic manner with an
early phase inhibition (<12 h) and a late phase activation >48 h.
Based on these and our previous findings on IL-6 we speculated
that budesonide and O3 may interact on a common signaling
pathway involved in SP-D transcription in airway epithelial cells.
Two groups independently established that glucocorticoids
induced SP-D mRNA protein in vitro and in vivo (34,
35). These pioneering studies showed that hydrocortisone
and dexamethasone stimulated both sftpd mRNA and SP-D
protein in vitro and in vivo in the fetal rat lung. Since the
proximal promoter region of the SP-D gene does not contain
complete binding elements for the glucocorticoid receptor, it was
hypothesized that glucocorticoids indirectly induced expression
of the sftpd gene or work in concert with other binding
elements. The proximal promoter region of the human SP-
D gene has binding elements for C/EBP, NFAT, AP1, HNF-
3, and STAT3/6 that all contribute to transcription of SP-D
(55). Interestingly, Zhang et al. reported that STAT3 (an IL-
6 responsive transcription factor) can act as a co-activator
in glucocorticoid receptor signaling (56) and H2O2-treatment
directly phosphorylated STAT3 in airway epithelial cells (38). We
tested the role of STAT3 and the glucocorticoid receptor in SP-D
mRNA (sftpd) and protein expression. Dexamethasone induced
sftpd expression in human primary type II aleveolar epithelial
cells was abolished by blockade of either the glucocorticoid
receptor or STAT3. We established here that dexamethasone
induced sftpd mRNA and SP-D protein via the glucocorticoid
receptor and critically, STAT3. Recent evidence suggests that
O3-induced glucocorticoid insensitivity involves p38 MAPK,
MKP-1, and IL-17A. Inhibition of p38 MAPK prevented the
decreased the inhibitory effects of dexamethasone on O3
stimulated inflammation and IL-17A (18) and inhibition of IL-
17A reduced dexamethasone insensitivity in a mouse model
of chronic O3 exposure (74). Here we showed for the first
time that STAT3 is involved in glucocorticoid-induced SP-
D synthesis. Cooperation between the glucocorticoid receptor
and STAT3 may be crucial for SP-D synthesis in airway
epithelial cells.
There are likely many pathways that contribute to the BAL
SP-D levels in vivo, including but not limited to budesonide
treatment, O3 exposure, and BAL IL-6 expression. Since
glucocorticoids are known to have numerous side effects and
after chronic administration patients can become refractory,
novel asthma therapeutics to induce SP-D may seek to directly
activate STAT3 signaling (5).
While prior work suggested that O3 may impair the
effectiveness of budesonide, here we studied the potential role
for SP-D in this pathway. We propose a novel SP-D-mediated
mechanism for the anti-inflammatory and functional effects of
budesonide on the lung. A better understanding of how air
pollutants such as O3 might affect asthma treatment will lead to
improved therapeutic approaches.
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